Posted by Michael Wonder on 17 May 2022
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland.
In early March 2022, Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program announced similar public formulary coverage.
